HealthcareServices

Glioma Treatment Market Anticipated to Record Steady Gains, Advancing to $7.44 Billion by 2030

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glioma treatment market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Glioma Treatment Market reach by 2030 starting from 2026 levels?

The glioma treatment market size has experienced strong growth in recent years. It is projected to expand from $5.37 billion in 2025 to $5.72 billion in 2026, at a compound annual growth rate (CAGR) of 6.4%. The expansion observed in the past can be linked to advances in neurosurgery, the development of radiation oncology, the adoption of chemotherapy, improvements in diagnostic imaging, and the increased availability of cancer care facilities.

The glioma treatment market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $7.44 billion, exhibiting a compound annual growth rate (CAGR) of 6.8%. This expansion throughout the forecast period stems from factors such as precision oncology integration, development of novel targeted drugs, improved survival outcome focus, expansion of specialty oncology clinics, and personalized treatment protocols. Key developments expected during this time frame involve increased use of combination therapy approaches, rising focus on early surgical intervention, expansion of targeted drug therapies, growing role of radiation therapy optimization, and improved long-term disease management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10689&type=smp

Which Drivers Are Influencing Long-Term Growth In The Glioma Treatment Market?

The increasing need for personalized medicine is anticipated to fuel the expansion of the glioma treatment market in the future. This approach involves tailored healthcare strategies that consider distinct patient characteristics such as genetics, environmental factors, and lifestyle choices, aiming to improve the efficacy and results of treatments. A multitude of elements, including progress in genomics, increased patient autonomy, and enhanced treatment effectiveness, are contributing to the rising demand for personalized medicine. Discovering biomarkers associated with gliomas facilitates the prediction of treatment responses and outcomes, thereby allowing for the creation of individualized treatment plans specifically designed for each patient’s unique profile. As an example, in February 2024, data from the Personalized Medicine Coalition, a US-based non-profit organization, indicated that the FDA sanctioned 16 novel personalized therapies for patients with rare diseases in 2023, an increase from six in 2022. Consequently, the escalating need for personalized medicine is a key driver for the growth of the glioma treatment market.

How Is The Glioma Treatment Market Divided Into Segments?

The glioma treatment market covered in this report is segmented –

1) By Type: Low-Grade, High-Grade

2) By Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Other Diseases

3) By Route Of Administration: Oral, Parenteral, Other Routes

4) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Drug Therapy, Other Treatments

5) By End-User: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Low-Grade: Astrocytoma, Oligodendroglioma, Mixed Glioma

2) By High-Grade: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma

What Upcoming Trends Are Likely To Define The Future Path Of The Glioma Treatment Market?

Leading companies in the glioma treatment market are adopting new, innovative products like immunotherapies to enhance patient outcomes and more effectively target tumors. Immunotherapies are treatments designed to stimulate or utilize the body’s immune system to recognize and attack cancer cells. For instance, in June 2024, Servier Pharmaceuticals, a France-based pharmaceutical company, secured FDA approval for VORANIGO (vorasidenib) tablets, marking a significant milestone as the first targeted therapy specifically for Grade 2 IDH-mutant glioma. Vorasidenib acts as a dual inhibitor, targeting isocitrate dehydrogenase (IDH) 1 and 2 mutations, which are frequently observed in gliomas. These mutations lead to the production of 2-hydroxyglutarate (2-HG), a metabolite that promotes the growth and survival of tumors. By inhibiting these enzymes, vorasidenib lowers 2-HG levels, potentially slowing down tumor progression.

Which Major Firms Are Strengthening Their Position In The Glioma Treatment Market?

Major companies operating in the glioma treatment market are Merck & Co Inc., Amgen Inc., F Hoffmann-La Roche AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Arbor Pharmaceuticals LLC, Amneal Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Bristol-Myers Squibb Co., Rigel Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Emcure Pharmaceuticals Ltd., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Sanofi S.A., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Bayer AG, Gilead Sciences Inc., Ipsen Pharma, Eisai Co. Ltd., Genentech Inc., Iovance Biotherapeutics Inc., Agios Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Glioma Treatment Market?

North America was the largest region in the glioma treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global glioma treatment market report during the forecast period. The regions covered in the glioma treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glioma Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10689&type=smp

Browse Through More Reports Similar to the Global Glioma Treatment Market 2026, By The Business Research Company

Glioblastoma Multiforme Gbm Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-gbm-treatment-global-market-report

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Pontine Glioma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795